1. UCB Immunology
Patient Value
Unit
November 2015

2. An international executive team
Iris Löw-Friedrich
Development and
Medical
Ismail Kola
New Medicines
Emmanuel Caeymaex
Immunology
Jeff Wren
Neurology
Jean-Christophe Tellier
CEO
Detlef Thielgen
Finance
Fabrice Enderlin
Talent & Company Reputation
Anna Richo
Legal
Mark McDade
Patient Value Operations
Bharat Tewarie
Strategic Marketing

4. What UCB stands for

5. UCB, the right size biopharma partner Focusing on treating patients with severe diseases in Neurology, Immunology, Bone
A “Right-Sized”(1) Biopharma company
€3.3 billion revenues in 2014
Strong investment in R&D (~25% of revenue)
Global footprint, with operations in ~40 countries
~8,500 employees
Euronext listed
(1) your product will reach patients in all key markets and get the attention it deserves, including from our senior leadership

6. 3 core medicines for patients with severe diseases
Rheumatoid arthritis
psoriatic arthritis (PSA)
ankylosing spondylitis (AS) – US
axial spondyloarthritis (AxSpA) – EU
Crohn’s disease
Epilepsy adjunctive therapy
Parkinson’s disease
Restless legs syndrome

7. Other key products Keppra® (levetiracetam)
Epilepsy adjunctive therapy (also in monotherapy in Europe) – Sold as E Keppra® in Japan
Keppra XR® (levetiracetam – Extended-release tablets) – U.S. only
Epilepsy adjunctive therapy
Zyrtec® (cetirizine HCl)
Seasonal allergic rhinitis
Xyzal® (levocetirizine dihydrochloride)
Allergies and chronic idiopatic urticaria

8. Moving forward - seeking additional R&D partnerships
Phase 1
Phase 2
Phase 3
romosozumab(1)
osteoporosis - postmenopausal women
Phase 3 results: H1 2016
osteoporosis – men
Phase 3 results: H2 2016
UCB0942 (PPSI)
highly drug resistant epilepsy
Phase 2 results: Q4 2016
bimekizumab / UCB4940 (IL17AF)
psoriatic arthritis
Phase 2a results: H2 2015
bimekizumab & Cimzia® combo
rheumatoid arthritis
Phase 2a results: H1 2017
UCB5857 (PI3K Delta inhibitor) immune-inflammatory diseases
Phase 2 start: H2 2015
dapirolizumab pegol (CD40L antibody)(2)
systemic lupus erythematosus
Phase 2 start: 2016
UCB7665
immunological diseases
UCB4144 / VR942(3)
asthma
neurology
immunology
bone
(1) partner: Amgen (2) partner: Biogen (3) partner: Vectura

9. Cutting-edge research and science
Addressing unmet patient needs and delivering breakthrough medicines
Two main Research Centers
World-class expertise in selected therapeutic areas and disease mechanisms
Connecting science in new ways - chemistry (small, chemically-derived molecules) and biology (large antibody-based molecules),
to leverage the potential of these two disciplines
‘Open innovation’ model based on strong partnerships with other biotech companies and prominent universities
Biologics pilot plant – Braine-l’Alleud, Belgium
Biologics R&D centre - Slough, U.K.
Two main Research Centers

10. Where can you be sure an asset will deliver transformational Benefit?
Pre-clinical
Phase 1
Phase 2
Phase 3
Cost Increase
Decisions Get More Difficult
(Emotional/Financial)

11. Partnering in Immunology - leveraging respective strengths in research, development and commercial capabilities
2015
Development & Commercial
Cimzia in PsO
2014
Research & Development
Peptide combination to address high unmet need in Type 1 Diabetes
2012
Research collaboration
Exploring the microbiome
Selected partnerships in Neurology

12. Everything we do starts with a simple question: “How will this make a difference to the lives of people with severe diseases?” 12